Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is well-positioned in the fast-growing field of allogeneic iNKT cell therapy, which offers distinct advantages over traditional therapies for cancer and other immune-mediated diseases. With a strong pipeline of innovative products, including the promising agenT-797, and a focus on single segment operations, the company has a solid foundation for future success. While additional financing may be needed in the coming years, the company's cash runway into late 2026/early 2027 and strong intellectual property protection provide reassurance for long-term investors.

Bears say

MiNK Therapeutics is facing decreased operating expenses and has a low cash balance, which may hinder its ability to advance its product candidate agenT-797 in its clinical trials. Additionally, the company’s reliance on external funding for its Phase 2 trials may not lead to significant R&D expenses, limiting its ability to effectively develop and bring its product to market. With a lowered discount rate, the company may have more financial flexibility, but the uncertainty surrounding its product and funding sources leads to a negative outlook on its stock.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.